Skip to Content

Join the 'Peripheral T-cell Lymphoma' group to help and get support from people like you.

Peripheral T-cell Lymphoma News

Related terms: PTCL

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Peripheral T-cell Lymphoma, Mantle Cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white blood cell in which most types of non-Hodgkin lymphoma occur. One-third of 32 patients treated with the modified T-cells experienced a complete remission of their non-Hodgkin lymphoma. And those pretreated with more aggressive chemotherapy did even better, researchers report. "It's a fantastic step forward," said Susanna Greer, director of clinical research and immunology at the American Cancer Society. "It's been difficult to make a lot of progress in lymphoma, especially in non-Hodgkin lymphoma, ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Waldenström Macroglobulinemia, Mycosis Fungoides, Peripheral T-cell Lymphoma, Mantle Cell Lymphoma

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Burkitt Lymphoma, Testicular Cancer

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

Posted 3 Jul 2014 by Drugs.com

July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. PTCL comprises a diverse group of rare diseases in which lymph nodes become cancerous. In 2014, the National Cancer Institute estimates that 70,800 Americans will be diagnosed with NHL and 18,990 will die. PTCL represents about 10 to 15 percent of NHLs in North America. Beleodaq works by stopping enzymes that contribute to T-cells, a type of immune cell, becoming cancerous. It is intended for patients whose disease returned after treatment (relapsed) or did not respond to previous treatment (refractory). “This is the third drug that has been approved since 2009 for the treatment of peripheral T-c ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma

Posted 3 Jul 2014 by Drugs.com

THURSDAY, July 3, 2014 – Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes). Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute estimates. Beleodaq is designed to inhibit immune cells called T-cells from becoming cancerous, the FDA explained Thursday in a news release. The drug is intended for people whose cancer has returned or who didn't respond to a prior therapy, the agency said. Beleodaq's safety and effectiveness were evaluated in clinical studies involving 129 people with PTCL. All were treated with the newly approved drug, and about 26 percent had their cancer disappear or shrink, the FDA said. The most common side ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma

Related Drug Support Groups

Folotyn, Istodax, Beleodaq, belinostat, romidepsin, pralatrexate